AustraliaMelbourne-based biotechnology firm Amplia Therapeutics has partnered with pharmaceutical giant Eli Lilly & Company to test a new combination therapy targeting non-small cell lung cancer (NSCLC). The collaboration involves evaluating Amplia's investigational FAK blocker drug, narmafotinib, alongside Eli Lilly's KRAS G12C inhibitor, olomorasib, in a Phase 1b/2b clinical trial. This trial aims to assess the safety and effectiveness of the combined treatment as a second-line option for advanced NSCLC patients with specific genetic mutations. The study will take place in Australia and the United States, with Eli Lilly providing the olomorasib drug at no cost. The partnership represents a strategic expansion for Amplia into the growing NSCLC market, which is projected to exceed $60 billion by 2033.
Bias read (Center): The article discusses a medical research collaboration focused on developing a new cancer treatment. There is no indication of political controversy, ideological framing, or biased language. The content remains strictly scientific and factual, focusing on the development of a potential therapeutic,
